BOSTON, Sept. 11, 2014 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced that clinical technology
companies CRF Health and Clinical Ink have joined its
Perceptive® Partner Program. Through the
program, technology, consulting, reseller and training companies,
as well as contract research organizations (CROs), can enhance and
broaden their services to biopharmaceutical customers by leveraging
the Perceptive® MyTrials eClinical platform along with
clinical and technical support services.
Perceptive® MyTrials is one of the industry's
leading suites of applications for managing clinical trials. Its
flexible, open architecture allows partners to integrate targeted,
specialized solutions within the platform. This gives their
sponsor customers efficient access to clinical data and
applications from a single source, allowing them to more
efficiently and effectively manage critical trial activities.
"To better ensure the safety and timeliness of their trials, our
customers are increasingly seeking efficient approaches to patient
screening, enrollment and randomization," said Rachael Wyllie, CEO of CRF Health. "As a
Perceptive partner, we can address these needs by integrating our
electronic Clinical Outcome Assessments [eCOA] offering with
Perceptive MyTrials randomization and electronic data capture
technologies."
Ed Seguine, CEO of Clinical
Ink,said, "Integrating solutions from Perceptive®
MyTrials into our SureSource® clinical platform
will provide sponsors with proven trial management solutions in a
user-friendly tablet PC system. This presents a powerful
combination of functionality and mobility."
As study designs become increasingly complex, sponsors are
relying on eClinical technologies to manage protocols and evolving
regulatory requirements. Developed in 2013 and consisting of
an ecosystem of technology and CRO partners, the
Perceptive® Partner Program offers support services
and training that enable service providers to integrate their
offerings with individual or collective Perceptive®
MyTrials applications including:
- DataLabs® Electronic Data Capture (EDC)
- ClinPhone® Randomization and Trial Supply
Management (RTSM)
- IMPACT® Clinical Trial Management System
(CTMS)
- Electronic Patient Reported Outcomes (ePRO)
- Medical Imaging
- Perceptive MyTrials® Data-Driven Monitoring
- LIQUENT® Insight® Regulatory
Information Management
"Sponsors continue to seek fully integrated, best-of-breed
technology solutions and clinical outsourcing services that can be
efficiently managed," said Graham
Bunn, Vice President, Perceptive Partner Program. "Adding
CRF Health and Clinical Ink to our partner program further
reinforces its value proposition as the industry's premier
partnership initiative for simplifying drug development."
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 80 locations in 51
countries around the world, and has approximately 15,560
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
About CRF Health
CRF Health is a leading provider of
electronic Clinical Outcome Assessment (eCOA) solutions for global
clinical trials. With experience in more than 475 trials,
over 100 languages and across 74 countries, CRF Health's TrialMax
eCOA solutions consistently demonstrate the industry's highest data
accuracy, patient and site compliance, and patient
retention. CRF Health's TrialMax eCOA solutions improve
trial engagement by fitting into the lives of patients and
seamlessly integrating into sites to maximize protocol
compliance. Their eCOA solutions include PROs (Patient
Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs
(Clinician or Rater Reported Outcomes).
About Clinical Ink
With offices in Winston-Salem, NC and Philadelphia, PA, Clinical Ink is an
innovation-driven eSource solutions company committed to delivering
technology that makes clinical research easier for sites, sponsors,
subjects and regulators. Developers of SureSource®,
the first purpose-built eSource solution providing cleaner data
faster, Clinical Ink is dedicated to eliminating paper documents in
clinical research. Additional information about Clinical Ink
is available at www.clinicalink.com or by calling toll-free
800-301-5033.
PAREXEL, Perceptive, Perceptive MyTrials, ClinPhone, DataLabs,
IMPACT, and LIQUENT are trademarks or registered trademarks of
PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates,"
"plans," "expects," "intends," "appears," "estimates," "projects,"
"will," "would," "could," "should," "targets," and similar
expressions are also intended to identify forward-looking
statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Annual Report on Form 10-K for the fiscal year ended June 30, 2014 as filed with the SEC on
August 20, 2014, which "Risk Factors"
discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, Vice President,
Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International Corporation